Core Laboratories (CLB) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was $123.6 million, down 4% sequentially and 5% year-over-year, impacted by seasonality, geopolitical conflicts, and expanded sanctions.

• Net income ex-items was $6.7 million; GAAP net loss was $0.2 million, with operating income and EPS also declining sequentially and year-over-year.

• Operating income fell 48% year-over-year and 69% sequentially, reflecting margin compression and higher non-operating charges.

• The company remains focused on technology investments, cost realignment, and strengthening its balance sheet.

• Free cash flow improved to $3.9 million, up over 50% year-over-year, driven by better working capital management.

Financial highlights

• Q1 2025 revenue: $123.6 million, down 4–5% sequentially and year-over-year.

• Net income ex-items: $6.7 million; GAAP net loss: $0.2 million.

• EPS ex-items: $0.14, down from $0.22 in Q4 and $0.19 last year; GAAP EPS: $0.00.

• Free cash flow: $3.9 million after $2.8 million CapEx; free cash flow margin improved year-over-year.

• Net debt reduced by $4.9 million to $103.9 million; leverage ratio at 1.31, lowest in eight years.

Outlook and guidance

• Q2 2025 revenue projected at $128–$134 million, with operating income of $13.1–$15.7 million and EPS of $0.17–$0.21.

• International upstream project activity expected to remain steady; US onshore market more sensitive to oil price volatility.

• CapEx for 2025 expected at $14–$16 million, excluding insurance-covered rebuilding.

• Effective tax rate for 2025 projected at 25%.

• Global oil and gas demand is expected to grow, but tariffs and OPEC+ production increases add uncertainty.